Axsome Therapeutics (AXSM) Other Operating Expenses (2020 - 2026)

Axsome Therapeutics' Other Operating Expenses history runs 7 years deep, the most recent figure standing at $16.9 million for Q1 2026.

• In Q1 2026, Other Operating Expenses rose 31.18% year-over-year to $16.9 million; the TTM figure through Mar 2026 stood at $101.6 million (up 36.87% YoY), while the FY2025 annual figure was $51.4 million, down 24.24% from the prior year.
• Other Operating Expenses came in at $16.9 million for Q1 2026 at Axsome Therapeutics, down from $51.1 million in the prior quarter.
• In the past five years, Other Operating Expenses ranged from a high of $52.2 million in Q4 2023 to a low of -$45.3 million in Q3 2022.
• A 5-year average of $13.1 million and a median of $12.0 million in 2023 frame the typical range for Other Operating Expenses.
• Across the five-year window, Other Operating Expenses tumbled 100.03% in 2022 and soared 90170.07% in 2023, its largest moves.
• Axsome Therapeutics' Other Operating Expenses stood at -$57946.0 in 2022, then jumped by 90170.07% to $52.2 million in 2023, then sank by 55.73% to $23.1 million in 2024, then soared by 120.98% to $51.1 million in 2025, then sank by 66.93% to $16.9 million in 2026.
• According to Business Quant data, Other Operating Expenses over the past three periods registered $16.9 million, $51.1 million, and $26.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison